CorMedix sets $8.32 DefenCath payment rate as it prepares Heron asset purchase
The company reported $355M in cash and $54.5M in quarterly sales, tightened its profit outlook, and flagged a payment reset for DefenCath and a priority FDA review for REZZAYO.
16 Nov 2026 · CorMedix Inc. CRMD · Company news
CorMedix enters 2027 with a $355M cash balance, a pending acquisition and a lower, quarterly-adjusted reimbursement rate for its lead product. Management set out all three on its 12 November call alongside third-quarter results.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): CorMedix Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More EarningsAll →
Earnings
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
18 Nov 2026 · Prenetics Global Ltd PRE · Company news
Earnings
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
18 Nov 2026 · newcleo plc NWCL · Company news
Earnings
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
17 Nov 2026 · Iridex Corp IRIX · Company news
Earnings
Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth
17 Nov 2026 · Interpace Biosciences, Inc. IDXG · Company news
Earnings
Zentek reports C$15.2M six-month profit on impairment reversal; cash rises to C$13.6M
17 Nov 2026 · Zentek Ltd. ZTEKF · Company news
Earnings
Vivos Therapeutics regains Nasdaq equity compliance as Q3 revenue rises 24% sequentially
17 Nov 2026 · Vivos Therapeutics, Inc. VVOS · Company news